Nocion Therapeutics is developing novel small molecule CSCBs, “nocions,” that selectively affect actively firing nociceptors for the treatment of serious conditions involving cough, itch, and pain
Nocion Therapeutics is developing novel small molecule CSCBs, “nocions,” that selectively affect actively firing nociceptors for the treatment of serious conditions involving cough, itch, and pain
Transposon Therapeutics specializes in the development of genetic therapeutics for the treatment of neurodegenerative diseases.
COUR Pharmaceuticals is developing first-in-class therapies designed to achieve antigen-specific tolerance for immune-mediated disease.
Endogenex is shifting the treatment paradigm for people living with Type 2 Diabetes by resetting cellular signaling to help the body better manage blood sugar levels.
X4 Pharmaceuticals a leader in the discovery and development of novel therapies for the treatment of immune system diseases.
XyloCor Therapeutics is developing a novel gene therapy for unmet needs in advanced coronary artery disease.
Thryv Therapeutics is pioneering a precision medicine approach to treat patients with Long QT Syndrome and potentially other arrhythmias.
Specific Biologics is developing a next generation gene-editing platform to accurately edit cells in a target tissue to treat certain genetic diseases.
PIC Therapeutics is developing a new generation of therapeutics based on the modulation of RNA translation to improve how cancer is treated.
Notch Therapeutics is developing a next-generation pipeline of genetically tailored T-cell therapeutics derived from renewable stem cell sources for the treatment of high-impact diseases, with an initial focus on cancer.
Medexus Pharmaceuticals is developing a best-in-class portfolio of innovative and high-valued orphan treatments for rare disease.
Kisoji is developing leading next-generation multi-specific antibodies to address difficult targets in oncology and other diseases.
Kalgene is focused on the development of precision medicine therapeutics to slow the progression of Alzheimer’s disease.
Iterion Therapeutic is developing novel cancer therapeutics targeting nuclear β-catenin, a historically “undruggable” oncology target implicated in cell proliferation.
IMV is developing a novel suite of immunotherapeutics producing a more rapid, robust, and sustained immune response to target and treat specific diseases with unmet clinical needs.
Histosonics is developing a non-invasive, image-guided method of tumor destruction for more effective cancer treatment, based on the science of histotripsy.
GenEp is developing first-in-class highly selective compounds that treat rare genetic and treatment-resistant epilepsies.
G1 Therapeutics is focused on the development of small-molecule therapies to address high unmet needs in oncology including triple-negative breast cancer and extensive stage small cell lung cancer.
Fusion Pharmaceuticals is developing next-generation radio-pharmaceuticals as precision medicines for the treatment of cancer.
Exact Imaging is the world’s leader in high-resolution systems enabling real-time imaging and guided biopsies for prostate cancer.
enGene is developing a platform that has the potential to streamline the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues.
Endotronix is developing an integrated platform to provide proactive, comprehensive health management tools for patients suffering from advanced heart failure.
Edesa Biotech is developing new treatments to help patients with limited options for inflammatory and immune-related diseases.
DEKA Biosciences is developing novel cytokine therapies to drive treatments for cancer patients and control inflammatory diseases.
DAMONA Pharmaceuticals is on a mission to develop small molecule therapeutics to improve the lives of patients suffering from cognitive impairment as a result of depression and other diseases of aging.
Cyrano Therapeutics is developing a novel therapy to restore chronic loss of taste and smell function in patients.
At the interface of computational and experimental drug discovery, Congruence Therapeutics is designing novel small molecules to treat diseases caused by protein misfolding.
Cardiac Dimensions is developing a minimally invasive implantable product to treat mitral valve regurgitation associated with congestive heart failure.
Cadence Neuroscience is developing a novel neuromodulation therapy with the potential to treat many neurological diseases that cannot be adequately addressed with available treatment options.
Tackling the problem of resistance to current antifungal therapies, Bright Angel Therapeutics is developing novel therapeutics to treat these life-threatening invasive fungal infections.
BioTheryX is advancing a portfolio of first-in-class protein degraders to transform patient treatment across a wide range of inflammatory disorders and serious cancers.
Arclight Therapeutics is building a pipeline of early-stage companies focused on the development of novel therapeutics for neurodegenerative diseases.
AmacaThera is developing a unique, injectable hydrogel platform technology to deliver localized therapeutics that are long-lasting and applicable to several indications.
Corvia Medical is developing a catheter-delivered implant to reduce symptoms and hospitalizations, while improving the treatment of heart failure with preserved ejection fraction (HFpEF).
Antiva Biosciences is developing first-in-class topical therapies aimed at treating the pre-cancerous lesions caused by HPV infection.